GLP-1 drugs reduce colon cancer patient death rates

medicalxpress.com — November 11, 2025 at 04:01 PM UTC

GLP-1 drugs, including Ozempic and Wegovy, are linked to significantly lower death rates in colon cancer patients. A study of over 6,800 patients found those on GLP-1 medications had less than half the risk of dying within five years compared to non-users. Researchers suggest potential mechanisms include reduced inflammation and improved metabolic health, but further clinical trials are needed to confirm these effects.

With a significance score of 6, this news ranks in the top 0.3% of today's 33412 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:

Most significant articles on this story:

[5.9]

GLP-1 drugs may reduce colon cancer deaths, UC San Diego study suggests (sciencedaily.com)

1d 7h

Source

[5.0]

Ozempic and Mounjaro show over 50% reduction in bowel cancer death risk (oglobo.globo.com)

1d 3h

Source (Portuguese)

[4.9]

Ozempic and Mounjaro reduce heart attack and stroke risk in type 2 diabetes (sciencedaily.com)

1d 4h

Source

[4.7]

GLP-1 drugs may reduce colorectal cancer deaths, study finds (gizmodo.com)

1d 4h

Source

[4.7]

Weight-loss drugs may reduce death risk for colon cancer patients (deseret.com)

24h

Source

[4.5]

GLP-1 drugs show promise in reducing colon cancer deaths (webpronews.com)

<1h

Source

[4.3]

Weight loss drugs Ozempic and Wegovy may reduce colon cancer death risk (timesofindia.indiatimes.com)

14h

Source